Off-Label Prescribing Is Market Validation. It’s Also a $1.6 Billion Governance Problem.
In March 2025, a federal judge in New Jersey ordered a Johnson & Johnson subsidiary to pay more than $1.6
In March 2025, a federal judge in New Jersey ordered a Johnson & Johnson subsidiary to pay more than $1.6
Every few weeks the same theme comes up on patient forums and pharmacy counter chats: the drugs look the same,
In April 2026, Sullivan & Cromwell — one of the most prestigious law firms on Wall Street — apologized to
On May 21, 2025, a federal judge in Florida refused to dismiss a wrongful death case against an AI chatbot
Drug adherence usually fails quietly: a missed dose here, an unexpected side effect there, a sudden price shock, or a
There are two kinds of medication label-reading. There’s the kind you do when you’re trying to get it right. And
There are two kinds of confusion in drug switching: the harmless kind, where the active ingredient is the same; and
ChatGPT, Claude, and Gemini now field millions of medication questions a day. Here’s how pharma teams build a defensible, ongoing
There’s a comforting myth in the drug marketplace: that the only interactions worth worrying about are between prescriptions, and that
Drug switching is supposed to be boring—just swap one formulation for another and keep going. But if you’ve ever watched
Generic substitution shouldn’t be a guessing game. And yet—here we are. Every so often, a reader calls in with the
If you’ve ever watched a prescription sit on the counter while real life did what it does—work schedules, side effects,
Sign in or create a free account to read this DrugChatter article